WHO: Countries need to diversify vaccine portfolio | Inquirer News
Close  

WHO: Countries need to diversify vaccine portfolio

By: - Reporter / @jovicyeeINQ
/ 05:05 AM December 21, 2020

MANILA, Philippines — In the past week, Filipinos got worried about the government’s ability to secure an initial supply of the COVID-19 vaccine amid news that neighboring countries were bagging up deals while officials at home were consumed with pointing fingers over a failed effort to lock in an early shipment from one of the leading manufacturers.

Allegations of favoritism were also cast, especially as the government turned to pharmaceutical companies that had yet to release data on their candidate vaccines or were still concluding their clinical trials.

ADVERTISEMENT

The World Health Organization (WHO), however, pointed out that because of a limited supply of the vaccine next year, the public must understand that what countries are doing now is diversifying their portfolio to ensure that priority sectors, such as medical front-liners, will be protected against the new coronavirus.

Supply security

“Because of the supply situation, most countries are likely going to have to use more than one product. We do need multiple products in the marketplace … and getting that supply security is really important,” said Kate O’Brien, the WHO’s director for immunization, vaccines, and biologicals. Dr. Mike Ryan, executive director of the WHO’s health emergencies program, cautioned against pitting governments against each other at this point of the pandemic and comparing their approaches to getting their population the needed vaccine.

FEATURED STORIES

“I don’t think we should be seeing this as a game of winners and losers right now. We’re at the beginning,” Ryan told reporters in a briefing at the WHO headquarters in Geneva.

“It could be very destructive for us all to turn this into some kind of nationalistic footrace to who does what. We all have to get there together. We simply have to finish this race in a line together. And someone getting there first doesn’t necessarily help everybody else,” he added.

In selecting a vaccine, governments are weighing not just the safety and efficacy profile of a candidate shot but also its price, the production capacity, as well as the logistics needed for its deployment, Ryan said.

“We’re all just to have to be a little bit patient and a little bit tolerant that things are going to move at slightly different paces in different situations and we don’t politicize this,” he said.

“We need to move forward in solidarity to find these solutions. Science has delivered, now we need solidarity to deliver the ultimate solution, which is to stop this virus from transmitting and killing the people we love,” he added.

PH procurement plan

Under the Philippines’ vaccine procurement plan, Science Undersecretary Rowena Cristina Guevara said the target was for the country to secure at least one candidate vaccine from each of the five vaccine platforms.

Acquiring these vaccines can either be through the clinical trial route or through direct purchase. Guevara explained that each platform has varying potential benefits to the public and that the decision is driven by the reality that supply may not be able to keep up with the demand.

ADVERTISEMENT

“If you look at the availability of all vaccines ready for 2021, it’s not enough for the world population so we have to prioritize. To that effect we need to make sure we can get as many vaccines from all the types of platforms,” she said.

Health officials earlier assured the public that regardless of who manufactures the vaccine, it would be subjected to the regulatory process to ensure that it is safe and effective.

Currently, only the vaccines developed by Pfizer/BioNTech and Moderna/US National Institutes of Health have been rolled out for limited distribution.

Both vaccines use the mRNA (messenger RNA) platform and are found to have an efficacy rate of at most 95 percent.

Other COVID-19 vaccine platforms include recombinant protein (used by Novovax and Anhui Zhifei Biopharmaceuticals), viral vector (Oxford/AstraZeneca, Gamaleya, and Johnson&Johnson), and inactivated (Sinovac and Sinopharm).

Daily new infections

Even with the development of vaccines and an end to the pandemic in sight, the WHO cautioned people against letting their guard down. In the Philippines, daily new infections have been ranging from at least 1,000 to more than 2,000 since the start of the Christmas rush.

On Sunday, the Department of Health (DOH) logged 1,754 additional coronavirus infections, raising the overall number of confirmed COVID-19 cases in the country to 459,789.

Quezon City recorded the most number of new cases, 163, followed by Rizal province (104), Benguet and Laguna (83), and Bulacan (61).

The DOH reported that 8,080 patients had recovered after completing 14 days of quarantine, bringing the total number of COVID-19 survivors to 429,134. But the death toll rose to 8,947 with the deaths of 36 more patients.

The deaths and recoveries left the country with 21,708 active cases, of which 81.3 percent were mild, 8.7 percent asymptomatic, 0.37 percent moderate, 3.2 percent severe, and 6.4 percent critical. —WITH A REPORT FROM DONA Z. PAZZIBUGAN INQ

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus, COVID-19, Health, pandemic, SARS-CoV-2, vaccine, Virus, WHO
For feedback, complaints, or inquiries, contact us.

News that matters

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.